Skip to main content

Advertisement

Log in

5-Day vinblastine infusion for pancreatic adenocarcinoma

A phase II Southwest Oncology Group study

  • Clinical Studies
  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Valeriote FA, Bruce WR, Meeker BE: A model for the action of Vinblastine in vivo. Biophys J 6: 145–152, 1966

    Google Scholar 

  2. Owellen SB, Hartke CA, Hanis F: Pharmacokinetics of Vinblastine in humans. Cancer Res 37: 2597–2602, 1977

    Google Scholar 

  3. Yap HY, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL: Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64: 279–283, 1980

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Address for offprints: Southwest Oncology Group (SWOG-8237), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229-6197, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guy, J.T., Fleming, T., Pollock, T.W. et al. 5-Day vinblastine infusion for pancreatic adenocarcinoma. Invest New Drugs 8, 205–206 (1990). https://doi.org/10.1007/BF00177261

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00177261

Key words

Navigation